Dexcom (DXCM)
Technical, fundamental, and sentiment analysis with recent related videos.
DXCM rates Neutral overall. The fundamental read is bullish: the company passes 6 of 9 quality tests on the Piotroski F-Score; balance sheet is in the Safe zone (Altman Z = 7.05); revenue is growing about 17.1% per year; net income is growing about 36.7% per year. The technical picture is bearish: price is 5.6% above the 200-day moving average; 9.1% below the 50-day; the 50/200 relationship is in a Golden cross. Sentiment is bullish (composite 72/100), based on 8 news articles from recent coverage.
Revenue 3-year avg +17.1%. Net income 3-year avg +36.7%.
Price vs 20DMA -6.2%. RSI 34.3. Bollinger state: Inside Bands.
Composite score 72/100 from the AI judge, based on 8 news items, 0 television segments, and 0 videos.
Latest Market Read
Dexcom’s ratings split the picture. Fundamentals are Bullish: revenue averaged 17.1 percent per year and net income averaged 36.7 percent per year across three years. Technical is Bearish: the stock trades about 6.2 percent below its 20-day moving average and the Relative Strength Index (RSI), a momentum reading, sits at 34.3 while price remains inside the Bollinger Bands. Sentiment is Bullish, composite 72/100. The Bullish fundamentals and sentiment clash with the Bearish technicals, producing an Overall Neutral rating.
Recent news: Coverage in the Global Database of Events, Language, and Tone (GDELT) and media outlets highlights a NEJM CONNECT randomized trial showing Dexcom’s G7 improved outcomes in adults with Type 2 diabetes not on insulin, a clinical win for broader adoption. Reports also note an institutional buyer adding 8,659 shares and an insider Rule 144 sale filing, along with recent share weakness and upcoming Q3 results that could create volatility. Recent videos list Dexcom among top stock picks.